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ABSTRACT
In eukaryotic ribosome, the N domain of polypeptide
release factor eRF1 is involved in decoding stop sig-
nals in mRNAs. However, structure of the decoding
siteremainsobscure.Here,wespecificallyalteredthe
stop codon recognition pattern of human eRF1 by
point mutagenesis of the invariant Glu55 and
Tyr125 residues in the N domain. The 3D structure
of generated eRF1 mutants was not destabilized as
demonstrated by calorimetric measurements and
calculated free energy perturbations. In mutants, the
UAG response was most profoundly and selectively
affected. Surprisingly, Glu55Arg mutant completely
retained its release activity. Substitution of the aro-
matic ring in position 125 reduced response toward
all stop codons. This result demonstrates the critical
importance of Tyr125 for maintenance of the intact
structure of the eRF1 decoding site. The results
also suggest that Tyr125 is implicated in recognition
of the 3d stop codon position and probably forms
an H-bond with Glu55. The data point to a pivotal role
played by the YxCxxxF motif (positions 125–131) in
purine discrimination of the stop codons. We specu-
latethateRF1decodingsiteisformedbya3Dnetwork
of amino acids side chains.
INTRODUCTION
High ﬁdelity of termination of protein synthesis ensures the
formation of normal-sized polypeptide chains as encoded in
the genome. Translational termination is known to be medi-
ated by class-1 polypeptide release factors (RF1 and RF2 in
prokaryotes, eRF1 and aRF1 in eukaryotes and Archaea,
respectively) [reviewed in (1–5)]. When a nucleotide triplet
(referred to as termination, or stop, or nonsense codon) in
mRNA occupies the ribosomal A site, it is decoded by RFs
at the small ribosomal subunit.
For prokaryotes, it has been suggested that the second
and third nucleotides of the stop codons are decoded directly
by a linear ‘protein anticodons’ (PAT in RF1 and SPF in
RF2) (6–8).
For eukaryotes, it is now established that the speciﬁcity of
stop codon recognition is associated with the eRF1 rather than
the ribosome (9) and the recognition site is located in the
N domain of eRF1 as is evident from genetic in vivo data (10),
biochemical studies in vitro (11,12) and ‘molecular chimera’
approach (13). Data on multiple alignments of eRF1 amino
acid sequences with different stop codon speciﬁcities are also
consistent with this conclusion (14). The computer-assisted
hypothesis suggesting the existence of so-called ‘terminator’
tRNAs inside the large ribosomal RNA (15) is inconsistent
with the experimental data (9,13,16). Cross-linking experi-
ments showing the close proximity of the A-site-located
stop codon and eRF1 (17,18) and in particular cross-linking
with a NIKS tetrapeptide of the N domain (19) are also
consistent with the above mentioned conclusion.
There are signiﬁcant differences between the data obtained
by various approaches regarding the nature and position of
amino acidresiduesofeRF1implicated indecodingofthe stop
codons within the ribosome (10–14). This diversity of opin-
ions is probably not associated with the origin of eRF1 since
the eRF1 protein family is known to be highly conserved
(20–22) and, for instance, the data obtained with yeast and
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doi:10.1093/nar/gki927human eRF1 should be fully compatible. Rather, the apparent
controversies may be derived by a methodological distinction
between in vivo and in vitro strategies or between genetic
versus biochemical approaches.
Here, we introduced various amino acid substitutions into
four positions in the N domain of human eRF1. Two of them,
55 and 125, are invariant in all class 1 eRF1s and aRFs and
occupied byGluandTyr,respectively. Twootherpositions, 51
and126,are variable ineRF1sfrom different species.Allthese
positions were mentioned earlier as potentially essential for
stop codon recognition based mostly on indirect evidence
(10,14,22,23). The generated mutants were examined
in vitro with respect to alterations of their functional and
physical properties. Ability of mutated forms of eRF1 to trig-
ger hydrolysis of fMet–tRNA (mimicking peptidyl–tRNA) in
the ribosome was tested. Mutants were also studied by differ-
ential scanning calorimetry to evaluate stability of the protein
globule after mutagenesis.
MATERIALS AND METHODS
Cloning and mutagenesis of human eRF1
The full-length cDNA encoding eRF1 with C-terminal His6-
tag fusion was cloned into pET23b(+) vector (Novagen) under
the control of phage T7 RNA polymerase promoter as
described previously (11,24).
The mutagenesis procedure was simpliﬁed by introducing
into human eRF1 cDNA a unique Bst98I site affecting neither
amino acid sequence nor the reading frame of human eRF1.
GeneEditor in vitro site-directed mutagenesis kit (Promega)
was used with the RFBst primer 50-CCATTCTTAAGCGGG-
CAAAACGCAAGG-30 (the Bst98I site underlined). The
resulting construct pERF4B containing the unique Bst98I
site within the gene encoding human eRF1 at positions
576–581 (T576C substitution) from the start ATG codon
was used for mutagenesis of human eRF1.
The mutagenesis procedure was performed according to the
PCR-based ‘megaprimer’ method (25). Two rounds of PCR
were performed with the same PCR mixture. The PCR primers
used for the generation of eRF1 mutants are available on
request (kissel@eimb.relarn.ru). For the M51 and E55
mutants the direct primer (RFNde), 50-GAGATATACA-
TATGGCGGACGACCC-30 (the NdeI site underlined)
together with one of the reverse primers for these mutants
were used in the ﬁrst round of PCR. In the second round
the ‘megaprimer’ synthesized in the ﬁrst round served as the
direct primer together with the reverse primer (RFBst) 50-CC-
ATTCTTAAGCGGGCAAAACGCAAGG-30 (the Bst98I site
underlined). For the Y125 and L126 mutants the direct RFBst
primer together with one of the reverse primers for these
mutants was used in the ﬁrst round. In the second round the
‘megaprimer’ synthesized inthe ﬁrst round served as the direct
primer together with the reverse RFNde primer. The resulting
590 bp PCR product was puriﬁed in low-melting NuSieve
GTG agarose (FMC Bioproducts) using DNA extraction kit
(Bio-Rad), hydrolyzed with NdeI and Bst98I, and ligated
with pERF4B plasmid, treated with the same endonucleases.
The ligated mixture was used for the transformation of
Escherichia coli, strain Z85. The cloned DNAs were
sequenced and appropriate clones were used for the expression
of the mutant eRF1s. The ﬁrst rounds of DNA ampliﬁcations
were carried out in 25 ml reaction mixtures containing 20 ng of
pERF4B DNA, 0.48 mM direct primer and 0.6 mM reverse
primer, 0.2 mM each of four deoxyribonucleoside triphos-
phates, 1· of Pfu DNA polymerase reaction buffer and
0.75 U of PfuTurbo DNA polymerase (Stratagene). The dena-
turation was carried out at 95 C (3 min) for the ﬁrst cycle, and
at 94 C (30 s) for the next 20–25 cycles. The ampliﬁcation
included 30 s of the primer annealing (60 C) and 40 s for
elongation (72 C). The second round of PCR was performed
after addition to the PCR mixture of 12 pmol of the reverse
primer (RFBst/RFNde) and 1.25 U of PfuTurbo DNA poly-
merase. Ampliﬁcation with ‘megaprimer’ was performed for
28 cycles at 94 C for 30 s, the appropriate annealing tempera-
ture Tm for the reverse primer for 40 s and at 72 C for 140 s for
elongation.
Expression and purification of human eRF1
and eRF3Cp
The wild-type human eRF1 and its mutants and the human
eRF3Cp containing His6-tags at the C-termini were produced
in E.coli, strain BL21(DE3), and puriﬁed using Ni-NTA
Superﬂow (Qiagen), as described previously (26,27). The
N-terminal amino acids (1–138) were absent in eRF3Cp with-
out any inﬂuence on its GTPase activity.
Ribosomes
Rabbit reticulocyte 80S ribosomes washed with 0.5 M KCl
were treated with puromycin and GTP for dissociation into
subunits which were subsequently resolved by centrifugation
in a 10–25% (w/v) sucrose gradient containing 0.3 M KCl,
3 mM MgCl2, 1 mM DTT and 20 mM Tris–HCl, pH 7.6.
Before addition to the incubation mixtures, the subunits
were combined in an equimolar ratio.
In vitro RF activity assay
The eRF1 activity was measured as described previously
(20,28) at saturating levels (50 mM) of one out of the three
stop-codon-containing tetraplets. The incubation mixture
(25 ml) contained 20 mM Tris–HCl, pH 7.5, 15 mM MgCl2,
8m MN H 4Cl, 1.5 pmol f[
35S]Met–tRNAf
Met–AUG–ribosome
complex and 4 pmol of eRF1. The background was measured
without tetraplet and subtracted from all values. AUG and
ribotetraplets were synthesized by A. Veniaminova and
M. Ryabkova (Institute of Chemical Biology and Fundamental
Medicine, Novosibirsk).
GTPase activity assay
GTPase activity was followed by accumulation of [
32P]Pi
using a modiﬁed charcoal precipitation assay as described
previously (29). Incubation mixture (50 ml) contained
20 mM Tris–HCl, pH 7.5, 30 mM NH4Cl, 15 mM MgCl2,
0.16 mM ribosomes, 0.16 mM human Cp and 10 mM
[g-
32P]GTP (800–2000 c.p.m./pmol); human eRF1 was
added in 0.04, 0.08 and 0.16 mM (ﬁnal concentrations). Reac-
tion was run at 30 C; 12.5 ml aliquots were withdrawn every
4 min and mixed with 0.5 ml of 5% activated charcoal sus-
pension in NaH2PO4, cooled on ice. The mixture was vortexed
and centrifuged at 9300 g for 15 min at 4 C. Aliquot of
supernatant (375 ml) was counted on scintillation counter.
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Measurements were performed using differential adiabatic
scanning microcalorimeter SCAL-1 (Scal Company,
Pustchino, Russia) in 0.32 ml glass cells. The rate of heating
was 1 K/min, in some cases 0.125, 0.5 and 2.0 K/min. Protein
concentration ranged from 0.3 to 2.0 mg/ml. Partial molar heat
capacity, Cp of proteins was determined as described previo-
usly (30). Partial molar protein volume was calculated from its
amino acid composition as recommended (31). The precision
of calorimetric enthalpy determination was 7 ± 1%; experi-
mental error of Td value did not exceed ±0.2 C. For analysis of
melting curves the MinScal programme (SCAL Company)
was used. Other details could be found elsewhere (32).
Calculation of free energy changes in human
eRF1 mutants
We performed the analysis of free energy perturbation (FEP)
caused by point mutations in human eRF1 as described pre-
viously (33,34). Brieﬂy, we implemented our analysis basing
on NAMD (http://www.ks.uiuc.edu/Research/namd/) FEP
module and self-designed script for ICM (www.molsoft.
com/). We selected the N domain of wt-eRF1 (positions
5–146) from the eRF1 crystal structure (1dt9) for introducing
point mutations. Free energy calculations were performed
as described previously (35,36). The N129A mutant was
modeled by 3D-JIGSAW programme (www.bmm.icnet.uk/
servers/3djigsaw/) and used as the model for introduction of
double mutation N129A+F131A.
RESULTS
Selection of amino acids positions for mutagenesis
Multiple alignments of amino acid sequences of eRF1 and
aRF1 are shown in Figure 1. The reasons to combine RFs
from different kingdoms of living matter relay on the close
structural homology between eRF1 and aRF1 (21). Evolution-
arily distant eRF1s are selected including organisms with vari-
ant genetic codes, e.g. Euplotes, Tetrahymena, etc. (22).
In recently suggested models for decoding site of eRF1
several residues are mentioned (10,14,22,23), including posi-
tions 51, 55, 125 and 126 (Figure 1). Some of these positions
are located on the surface of the eRF1 molecule as is evident
from crystal structure (37) and for these reasons amino acid
side chains in these positions are exposed to interaction with
ligands, e.g. mRNA. Moreover, positions 125 and 126 are
proximal to Cys127 which is known to be essential for decod-
ing function of eRF1 (12). Positions 55 and 125 are proximal
in space in eRF1 crystals (37). Collectively, these data point to
the necessity to analyze possible involvement of positions
mentioned above in decoding function of eRF1.
Positions 51 and 55
Position 51 is occupied in human eRF1 by Met residue which
is not conserved and varies considerably in both eRF1 and
aRF1 families (Figure 1). The RF activities of the M51L,
M51Y, M51D, M51R and M51E mutants have been tested
in an in vitro assay. All these eRF1 mutants retain full activity
Figure1.AlignmentoftheNdomainfragmentsfromeRF1andaRF1primarystructures.Residuenumberingisbasedonhumanwild-typeeRF1.TheshortenedLatin
namesaregiven.Accessionnumbersareinbrackets.Hundredpercentidenticalpositionsareblack-shadowed;80%identicalpositionsaregray-shadowed.Similarity
scoring is disabled.
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the wild-type eRF1 (data not shown). Since the substituting
amino acids are very different from the initial Met residue and
at the same time distinct among themselves, it implies that
the eRF1 function is tolerant to the nature of amino acid in
position 51.
In a sharp contrast with Met51, position 55 is occupied
exclusively by Glu (Figure 1). This may point to an essential
structural and/or functional role of this residue in eRF1/aRF1
protein superfamily. In fact, in E55A, E55S and E55Y mutants
the UAG response was entirely abolished, whereas only about
2- to 3-fold reduction of the RF activity took place with UGA
(Table 1). The UAG-selective inactivation was not due to
inability of the mutant proteins to bind to the ribosome as
the GTPase activity of eRF3 which was a measure of eRF1
codon-independentbindingtothe ribosome(12,26,29)wasnot
affected at all (data not shown). Relatively high remaining RF
activity (40–80%) toward UGA (Table 1) also spoke against
loss of binding capacity as a cause of UAG-speciﬁc loss of
function. Three E55 mutants seem to be the very ﬁrst cases
when a complete inactivation toward one stop codon response
was achieved though the mutant factor remained partially
active toward two other stop codons. The E55R mutant will
be discussed below.
Positions 125 and 126
We have shown earlier that two invariant amino acids, Cys127
and Phe131 (Figure 1), are critical for the functional integrity
of human eRF1 and presumably are implicated in the recog-
nition of the 2d position of the stop codon (12). We have now
mutagenized two other amino acid residues from the same
region, Tyr125 and Leu126. The ﬁrst amino acid, as is evident
from the alignment, is invariant while the second one, which
neighbors Tyr125 from the C side, is variable (Figure 1).
Functional activity of the Tyr125 mutants is given in
Table 1. Most remarkably, a single point mutation, Y125A,
causes loss of function toward all three stop codons. Introduc-
tion of Glu instead of Tyr also causes a profound and unspe-
ciﬁc loss of activity. The Tyr125Ser mutant is silent toward
UAG like Tyr125Ala mutant but retains half of its initial
activity with UGA (Table 1). The most interesting result
has been obtained with a mild substitution Tyr!Phe, i.e.
one aromatic amino acid is exchanged with another one.
Here, the decrease of the RF activity is highly selective: no
change in response to UAA and UGA but a 3-fold loss of
function toward UAG. Clearly, this selective inactivation is
not due to damage of binding to the ribosome: two other
activities are not affected at all and the GTPase activity of
eRF3 which is entirely dependent on the binding of eRF1 and
eRF3 to the ribosome as mentioned above remains as in the
presence of the wild-type eRF1 (Figure 2). Most likely, invari-
ant Tyr125 is essential for the UAG stop codon recognition.
The neighboring variable L126 has been found to be non-
essential for function since L126E, L126F and L126I mutants
possess the same activity toward all three stop codons as the
wild-type eRF1 (data not shown).
Hydrogen bonding between Glu55 and Tyr125
As follows from the structural analysis (Figure 3A) positions
55 and 125 are close in space and can form a hydrogen bond
between the hydrogen atom of OH group of Tyr125 and the
oxygen atom of the COO group of Glu55. The length of the
bond is equal to 1.73 s (Figure 3B). This suggestion is con-
sistent with the functional alterations observed with mutant
eRF1. When in the E55A mutant the acceptor group disap-
pears, the RF activity is completely lost toward the UAG stop
codon (Table 1). It is also ﬁve times diminished if Glu is
substituted with a shorter amino acid residue (Asp) leading
to increase in the distance between the acceptor and donor
groups forming the H-bond. The E55Q mutant has also a
3-fold reduced RF activity, possibly because the acceptor
COO group is converted into a potential donor CONH2
group. This group theoretically is able to form an H-bond
with OH group of Tyr125 causing an increase of the distance
between the interacting atoms (not <2 s). Moreover, due to
the neighborhood of the aromatic ring the donor property of
the Tyr125 OH group is signiﬁcantly weakened making an
H-bond between the Tyr125 and Gln55 unstable.
Our suggestion that Glu55 and Tyr125 form an H-bond is
consistent also with other observations. All Tyr125 mutants
tested so far (Table 1) reduce their RF activity if the donor
group of the amino acid side chain is lost. To explain a rather
surprising observation that the E55R mutant is completely
active (Table 1), we have inserted Arg instead of Glu in the
3D structure of eRF1 (Figure 3C). It turned out from the model
that an ‘inversion’ of the H-bond formation takes place.
Instead of H-bond acceptor in position 55, Arg becomes a
donor of H while oxygen of the Tyr OH group becomes an
acceptor. The distance between H of the NH group (Arg55)
and O of Tyr125 is equal to 1.82A (Figure 3C) which permits
H-bond formation. This is possible because the strong NH
group of Arg55 is able to bind even to weak OH acceptor
group of Tyr125.
Thermal denaturation of wild-type eRF1 and
its mutants
In principle, point mutations of invariant amino acids if they
playanessentialroleinmaintenanceof3Dstructureofthepro-
tein may cause changes in protein stability. The destabilization
Table 1. In vitro release activity of human Glu55 and Tyr125 eRF1 mutants
Mutant eRF1 Release activity (%)
UAAA UAGA UGAA
E55A 59 0 48
E55D 72 21 78
E55Q 75 35 80
E55R 98 97 104
E55Y 11 2 56
E55S 27 1 36
Y125A 5 6 8
Y125E 12 14 19
Y125F 100 34 100
Y125S 17 2 54
The release activity of mutant eRF1s was measured according to the in vitro
Caskey’s assay as described previously (20,28). Data are given in % versus the
wt-eRF1.Averagevaluesfromthreeindependentexperimentsruninduplicates
are presented. One-letter amino acid code is used. An error in RF activity
measurementsvariedfrom8.5to10%fordifferentmutants.Backgroundvalues
(without any stop codon) were subtracted everywhere.
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abolishment of RF activity.
To examine this possibility, we have measured a thermal
stability of eRF1 mutants in comparison with wild-type pro-
tein. As shown in Table 2, melting temperatures of the mutants
differ insigniﬁcantly from the Td of wt-eRF1. The results mean
that protein globule after point mutagenesis remains stable
enough and the functional alterations (Table 1) are not asso-
ciated with a destabilization of protein 3D structure. This
conclusion is supported by analogous analysis performed
with other eRF1 mutants (32).
The only apparent exception is Y125A mutant with
DTd ¼ 2.8 C (Table 2). However, most likely, it is not the
cause of functional damage because, for example, a double
mutant N129P + K130Q exhibits strong destabilization
(DTd ¼ 7.9 C) (32), whereas its RF activity was only partially
diminished toward UAG and was fully preserved versus two
other stop codons (12).
Changes in the calculated free energy of
eRF1 mutants
We have calculated the changes in free energy induced by
point mutations in eRF1 as described in Materials and Meth-
ods. In addition to E55 and Y125 mutants, we have performed
similar analysis for some previously described (12) mutants
(positions129and131).AsseenfromFigure4,changesinfree
energy of mutants in positions 55 and 125 are very small or
negligible and do not exceed 20 kcal/mol. This result means
that mutations in these positions do not destabilize the 3D
structure of eRF1 in full agreement with calorimetric measure-
ments (Table 2). At the same time the strong alteration of free
energy in double N129AF131A mutant (Figure 4) is consistent
with known involvement of these residues in intramolecular
interactions (37) and with known profound changes of func-
tional activity of this mutant (12). The case of this double
mutant demonstrates the sensitivity of the used methods:
free energy change calculated for the N129AF131A mutant
is 90 kcal/mol (Figure 2), which correlates with DTd ¼  6 C
(Table2,N10).Incontrast,forE55andY125mutantsthisfree
energy difference is  20 kcal/mol and consistent with very
small DTd values (Table 2). The Y125F is the only mutation
tested so far that slightly stabilizes eRF1 molecule (Figure 4).
DISCUSSION
Invariant amino acids, such as Glu55 and Tyr125, may be
essential for maintenance of spatial protein structure and/or
for decoding function of eRF1. We attempted to follow the
consequences ofpoint mutagenesis ofGlu55 and Tyr125 using
three strategies. First, we measured the thermal stability of
eRF1 mutants by differential scanning microcalorimetry and
found that the destabilization of protein conformation is in
most cases negligible with one exception for Y125A mutant
wheredecreaseinmeltingtemperatureismeaningful(Table2).
This observation implies that these positions in protein struc-
ture are not critical for protein stability as anticipated from
surface location of both residues in protein globule (37).
Second, we calculated possible changes of free energy of
eRF1 mutants in comparison with wild-type protein and
found very small alterations (Figure 4). This indicates that
the introduced substitutions do not disturb the protein con-
formation.These data arefullyconsistent with the calorimetric
Figure2.KineticsofGTPhydrolysiscatalyzedbyhumaneRF3inthepresenceoftheribosomesandeRF1mutants.Amountofwt-eRF1anditsmutantsareindicated
inpmoles.Eachtubecontained125pmolofGTP(800–2000c.p.m./pmol),2pmoloftheribosomes,2pmolofeRF3Cpandvaryingamountsofwt-ormutanteRF1.
An average from three independent experiments is shown. The experimental error was ±5%.
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mutants to induce GTPase activity of eRF3 within the ribo-
some (Figure 2). We have shown earlier that this assay reﬂects
the ability of mutated eRF1 to bind to the ribosome (29) and is
sensitive to some mutations in the N domain of eRF1 (12,24).
For all Glu55 and Tyr125 mutants tested so far, their ability to
activate eRF3 GTPase within the ribosome was the same as for
wt-eRF1. It means that codon-independent binding ability of
mutatedeRF1formstowardtheribosomeremainsundamaged.
Collectively, all three approaches speak against the possi-
bility that functional consequences of eRF1 mutagenesis are
associated with protein destabilization or distortion of the 3D
structure.
Substitution of the aromatic ring in position 125 makes the
eRF1 almost silent toward two or three stop codons (Table 1).
Figure3. StructureoftheNdomainofhumaneRF1(37).(A)Theribbonmodel
is represented. The YxCxxxF loop is shown by thin arrow. The side-chains of
essential residues Glu55 and Tyr125are shownas sticks. The H-bondis shown
as a black line. (B) Human wt-eRF1. (C) The Glu55Arg mutant.
Table 2. Melting temperatures of wild-type and mutant forms of human eRF1
No.
b Wild-type eRF1
and its mutants
Td ( C) DTd
a ( C)
1 Wild-type 55.3 0
2 E55R 54.4  0.9
3 E55D 55.8 +0.5
4 E55A 54.5  0.8
5 Y125A 52.5  2.8
6 Y125F 55.6 +0.3
7 N129A 53.7  1.6
8 N129P 48.6  6.7
9 F131A 52.6  2.7
10 N129A + F131A 49.3  6.0
aDTd ¼ Td (mutant)  Td (wt).
bMutantsnumbers7–10wereisolatedandfunctionallytestedearlier(12)andthe
calorimetricdata are taken from (32)to show the sensitivity ofthe calorimetric
method.
Figure 4. The molecular modeling analysis of free energy changes in eRF1
virtual mutants. The procedure included the whole molecule side-chain mini-
mization (100 calls, Newton method) followed by 1000 calls of both backbone
and side-chain energy minimization in 10 s sphere around the Ca-atom of the
target residue. The ICM molecular modeling program was used for minimiza-
tion procedures.
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tenance of the intact structure of the decoding site.
The UAG response is affected most strongly in the Glu55
and Tyr125 mutants (Table 1). This is the only stop codon
which has G in the third position while it has common U with
two other stop codons and shares A with UAA. Consequently,
Glu55 and Tyr125 are implicated in the recognition of the
G base in the UAG stop codon.
We assume that between Glu55 and Tyr125 an H-bond is
formed. This interaction may help to preserve close proximity
of the two remote regions of the N domain. Parallel UAG-
selective loss of RF activity in E55A and Y125F mutants
suggests that preservation of the H-bond between these resi-
duesisaprerequisite forUAG-dependent RFactivity.Therole
of Glu55 is less essential than Tyr125 because some other
amino acids in position 55 are able to partially substitute
Glu and, most surprisingly, Arg55 is as active as Glu55
(Table 1). Therefore, we suggest that in the Glu-Tyr pair
the major role is played by Tyr, whereas Glu is most likely
required for H-bond formation with Tyr125 to ﬁx it in a proper
orientation.
Since the functioning eRF1 is located within the ribosome
the Glu55-Tyr125 pair is probably surrounded by hydrophobic
environment and therefore water molecules will probably
not interfere with H-bond formation. Similar behavior of
intramolecular H-bonds in proteins has recently been dis-
cussed (38,39).
AlthoughweconsiderE55asinvariantaminoacid(Figure1)
it appeared very recently that in ciliate Loxodes striatus eRF1
(Swiss-Prot accession no. Q5CD84) this residue is substituted
byAla (40). L.striatus eRF1corresponds in this position toone
of our mutated forms of human eRF1 which has no RF activity
toward UAG (Table 1). Based on our results we infer that this
ciliate eRF1 possesses an altered stop codon recognition pat-
tern lacking UAG response. This prediction is fully consistent
with the fact that in this organisms only UGA servers as a
single stop codon while two other stop codons are reassigned
from sense codons (40).
The sets of amino acids recognizing A and G are different,
for example, Ser and Thr form H-bonds with A, while G
prefers Asn, Glu and Gly (41). We suggest that A and G in
the same position are recognized by non-identical sets of
amino acids.
In the previous work (12), an omnipotent human eRF1 has
been converted into unipotent factor recognizing only UGA
stop codon. The major role in this conversion is played by
Cys127 and/or Phe131. From these data, it is evident that these
amino acid residues can be implicated in recognition of A in
the second stop-codon position. The Cys residue can form an
H-bond with A while the aromatic ring of Phe can be involved
in van der Waals interactions with a purine heterocycle (41).
Thus, two purines in the UAG stop codon require for spe-
ciﬁc discrimination at least four amino acids probably with a
dominant role of Cys127 and Tyr125. The U base should be
discriminated by no less than two amino acids as predicted by
structural analysis (42). Therefore, we assume that stop codon
triplet requires for its speciﬁc recognition more than three
amino acid residues.
In previously published recognition models (14,23) Glu55
has been assumed to be involved in recognition of U, the ﬁrst
stop codon base. Our data clearly show that this amino acid
residue is not implicated in discrimination of U. The most
striking example is the E55R mutant, which is as active as
the wt-eRF1 toward all three stop codons (Table 1). Tyr125
and Cys127 have been also assumed to recognize the ﬁrst U
(14). This hypothesis contradicts our previous data (12) show-
ing the role of Cys127 in 2nd base discrimination but not the
ﬁrst. As shown here, mutations at Tyr125 do not profoundly
impair UGA response (Table 1) and therefore, most likely,
Tyr125 is not involved in U discrimination.
Leu126 has been proposed as an amino acid residue which
recognizes the second stop-codon base (10,14). However, sub-
stitutions in this position as shown here exhibit no effect on RF
activity toward all three stop codons.
In summary, the suggested models (10,14,23) are not sup-
ported by previous (12) and new (this work) data obtained by
directed point mutagenesis followed by in vitro determination
of RF activity versus all three stop codons. Previous models
were based on indirect genetic data (10), bioinformatics
approach (14,22) or molecular modeling (10,14,23).
We suggest that stop codon recognition is controlled by
many amino acid residues (at present only part of them are
identiﬁed) via a 3D network rather then by one amino acid–
one nucleotide interaction as proposed in the prokaryotic
recognition model (6). It is noteworthy that amino acid resi-
dues identiﬁed as being implicated in stop codon recognition
by eRF1s (Glu, Tyr, Cys and Phe) are distinct from those
involved in stop codon recognition in bacteria (Pro, Ala,
Thr, Ser and Phe) with one exception of Phe. This remarkable
difference most likely reﬂects profound dissimilarities
between eRF1/aRF1 and RF1/RF2 protein families in their
amino acid sequences (20,21,37) and 3D structures (37,43).
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